An inflammatory response can cause joint pain, or rheumatic heart disease, which scars heart valves and kills about 140 people in New Zealand each year. The treatment, also called secondary prophylaxis, aims to prevent infections that may lead to the recurrence of rheumatic fever and either cause or worsen rheumatic heart disease. Early studies to determine how BPG might work were conducted in healthy, fit, white, young military recruits aged between 18 and 24 years - none of whom had rheumatic fever or rheumatic heart disease. “This type of pharmacology research work would usually require large blood volumes from participants,” Sika-Paotonu said. Another study in Australia was targeting indigenous Aboriginal populations suffering acute rheumatic fever.
Source: Otago Daily Times January 03, 2018 01:18 UTC